Engineered T cells that target KRAS-mutated metastatic lung cancer
Project 2: Treating metastatic lung cancer by targeting mutated KRAS with engineered T cells
['FUNDING_OTHER'] · FRED HUTCHINSON CANCER CENTER · NIH-11196687
This project uses specially engineered immune cells to try to find and kill metastatic lung cancers that have KRAS gene mutations.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11196687 on ClinicalTrials.gov |
What this research studies
If your lung tumor has a KRAS mutation, researchers will change a type of your immune cell (T cells) in the lab so they better recognize that mutation, grow many of those cells, and then give them back to you. The goal is for the engineered T cells to seek out and destroy cancer cells that carry the KRAS mutation. This approach is aimed at metastatic non-small cell lung cancer that often becomes resistant to targeted drugs and checkpoint immunotherapy. The team combines lab work on patient tumor samples with clinical cell infusion methods to try to produce stronger and longer-lasting anti-tumor responses.
Who could benefit from this research
Good fit: Ideal candidates are people with metastatic non-small cell lung cancer whose tumors have an actionable KRAS mutation and who are healthy enough for cell therapy.
Not a fit: Patients whose tumors do not have KRAS mutations or who cannot safely receive cell infusions are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, this could shrink or control KRAS-mutant metastatic lung tumors and produce longer-lasting remissions than current options.
How similar studies have performed: Cell therapies have cured some blood cancers and helped melanoma, but directly targeting KRAS-mutant solid tumors is a newer strategy with only early clinical promise so far.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GREENBERG, PHILIP D — FRED HUTCHINSON CANCER CENTER
- Study coordinator: GREENBERG, PHILIP D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.